Novavax COVID-19 Omicron vaccine

As the SARS-CoV-2 virus continues to evolve, Novavax is evaluating a variant strain vaccine based on the Omicron (B.1.1.529).

In December 2021, Novavax began developing an Omicron-specific variant vaccine and within weeks we initiated GMP manufacturing. A clinical trial of this vaccine candidate is ongoing, for more information visit ClinicalTrials.gov.